NCT04958811View on ClinicalTrials.gov

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-squamous Non-small-cell Lung Cancer
Interventions
DRUG

Tiragolumab

600mg IV administered every 3 weeks.

DRUG

Atezolizumab

1200mg IV administered every 3 weeks.

DRUG

Bevacizumab

15mg/kg IV administered every 3 weeks.

Trial Locations (2)

20007

MedStar Georgetown University Hospital, Washington D.C.

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Georgetown University

OTHER